Dyne Therapeutics: head of R&D and CMO Kerr Douglas received 20,000 shares

What happened

• Kerr Douglas, head of R&D and CMO, received 8,000 restricted stock units and 12,000 restricted stock units recorded as a derivative on Oct 20, 2026, at $0 per share, total $0.

Key details

• Transaction date(s) and price(s): Oct 20, 2026; price reported $0 for both entries.
• Shares acquired: 8,000 RSUs (F1) and 12,000 RSUs (derivative).
• Holdings mentioned in the filing: filing notes include 133,126 unvested RSUs (F2).
• Vesting and related footnotes:
  • F1: the 8,000 RSUs vest in equal quarterly installments over four years, first vesting on Jan 20, 2027.
  • F2: includes 133,126 unvested RSUs (as reported).
  • F3: the filing states an option was granted on Oct 20, 2026, with underlying shares scheduled to vest over four years in equal monthly installments through Oct 20, 2030.
• Filing date: Form 4 was filed on Oct 22, 2026.

Why it may matter

• These transactions were awards of restricted stock units and a derivative RSU grant, not open-market purchases or sales.
• The RSUs have vesting schedules (see F1 and F3) that determine when shares may be issued.
• This filing does not show why the insider traded or why the company acted.